Breaking News

Advanced BioMatrix Acquires HyStem from Lineage Cell Therapeutics

Advanced BioMatrix to fully manufacture and distribute the HyStem kits.

Advanced BioMatrix has acquired the HyStem line of products from Lineage Cell Therapeutics, previously BioTime/ESI Bio/Glycosan. HyStem kits are based on thiolated hyaluronic acid technology. With HyStem, researchers can create customizable 3D hydrogels for culturing cells whose natural environment is rich in hyaluronic acid. This acquisition includes the transfer of technology, intellectual property, know-how and assets for the manufacturing and sale of HyStem products for research and develop...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters